ERBB2 and glioblastoma: In the phase I clinical trial CAR2BRAIN, intrathecal administration of genetically engineered NK-92/5.28.z cells during relapse surgery is being tested at the University Hospital Frankfurt in patients suffering from recurrent HER2+ glioblastoma (GB) [88].